Biotech

  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip
    Obesity drugs

    AstraZeneca exercises option to buy an obesity startup

    The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

    By • Nov. 6, 2025
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Vaccines

    Moderna leans on cost cuts, pipeline as vaccine sales dip

    Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to break even financially in 2028 with the help of more disciplined spending. 

    By • Nov. 6, 2025
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • An illustration of a stock market graph and bar chart price display.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Evommune nabs $150M in IPO amid federal shutdown

    The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities law to price an offering during the shutdown. 

    By • Nov. 5, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Soleno slumps despite sales uptick; Madrigal’s MASH drug continues ascent

    Soleno shares fell double digits amid questions about the growth trajectory of its Prader-Willi drug. Elsewhere, a cancer medicine at the center of a $1.9 billion buyout fell short in a key trial. 

    By BioPharma Dive staff • Nov. 5, 2025
  • Portrait of a brown-haired man smiling at the camera.
    Image attribution tooltip
    Permission granted by HI-Bio
    Image attribution tooltip
    Emerging biotech

    Braveheart secures $185M to advance challenger to Bristol Myers heart drug

    The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

    By • Nov. 5, 2025
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Vertex’s new pain, blood disorder drugs miss Wall Street expectations

    While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

    By • Nov. 4, 2025
  • A Sarepta logo is displayed on a building in Cambridge, Massachusetts on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Sarepta Duchenne drugs come up short in confirmatory test

    Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and that the evidence accrued to date makes a strong case for full approval.

    By • Nov. 4, 2025
  • A 3D visualization of antibody drug conjugates.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Startup launches

    Neok Bio launches with $75M to make dual-targeting ADCs

    The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by simultaneously homing in on “unique pairs” of cancer targets. 

    By • Nov. 4, 2025
  • Employees of biotechnology company UniQure work in a laboratory.
    Image attribution tooltip
    Courtesy of UniQure
    Image attribution tooltip

    UniQure dives after FDA’s ‘very surprising’ reversal on Huntington’s gene therapy

    The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as it's been in years, some analysts said.

    By • Nov. 3, 2025
  • A 3D rendering of the CRISPR-cas9 gene editing system.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Caribou results suggest renewed promise for ‘off-the-shelf’ cancer cell therapy

    While early, the data support Caribou’s plan to boost its therapies’ effectiveness by using donor cells that are carefully matched to a patient’s immune system. 

    By • Nov. 3, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark

    George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.

    By BioPharma Dive staff • Nov. 3, 2025
  • Two of Manifold Bio's co-founders, Pierce Ogden and Gleb Kuznetsov, pose in the company's labs.
    Image attribution tooltip
    Permission granted by Manifold Bio
    Image attribution tooltip
    Brain drug revival

    Roche taps an AI specialist to craft new brain drugs

    For $55 million, Roche gains access to Manifold Bio’s drug discovery technology, which will be used to develop new “shuttles” that can get medicines across the blood-brain barrier.

    By • Nov. 3, 2025
  • A drop of liquid is held via a pipette above a row of vials.
    Image attribution tooltip
    deliormanli via Getty Images
    Image attribution tooltip
    Emerging biotech

    Corporate venture firms stepped in for drug startups during biotech funding pullback

    According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

    By • Oct. 31, 2025
  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win

    Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.

    By , • Oct. 30, 2025
  • Intellia Therapeutics
    Image attribution tooltip
    Permission granted by Intellia Therapeutics
    Image attribution tooltip
    Gene editing

    FDA places formal hold on two Intellia CRISPR trials

    Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that makes a longer halt more likely. 

    By • Oct. 30, 2025
  • A person points to the start of a successful business on a blue stock market graph.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BridgeBio chalks up another win for its rare disease research

    The company reported its second late-stage study success, this time with a drug that could become a new treatment standard for an uncommon endocrine disease.

    By • Oct. 29, 2025
  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK adds to COPD drug push with Empirico deal

    GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a "broad spectrum" of people with the chronic lung condition. 

    By Kristin Jensen • Oct. 28, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Incyte trims pipeline; Zenas surges on MS drug results

    Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the federal government shutdown and GSK picked up a cancer drug.

    By BioPharma Dive staff • Oct. 28, 2025
  • Jason Cole and John Kulman of Zag Bio.
    Image attribution tooltip
    Permission granted by Zag Bio
    Image attribution tooltip
    Startup launches

    Zag Bio emerges with plans to treat immune disease by targeting the thymus

    With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag “tolerizing” antigens to the thymus.

    By • Oct. 28, 2025
  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin, following sluggish sales, to offload hemophilia gene therapy

    The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three years of slow uptake for a medicine once viewed as a future blockbuster.

    By • Oct. 27, 2025
  • A photograph of Intellia scientists in the lab
    Image attribution tooltip
    Courtesy of Intellia Therapeutics
    Image attribution tooltip
    Gene editing

    Intellia pauses two CRISPR drug studies after safety scare

    A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver stress, prompting the company to pause enrollment and dosing while evaluating a new safety protocol. 

    By • Oct. 27, 2025
  • A photo of BridgeBio Pharma CEO Neil Kumar
    Image attribution tooltip
    Permission granted by BridgeBio Pharma
    Image attribution tooltip

    BridgeBio to seek approval of limb-girdle drug following new study data

    The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle stability that one executive described as a “home run.”

    By • Oct. 27, 2025
  • An illustration of red blood cells
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Hemab collects another $157M to go after ‘underserved’ blood diseases

    The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation disorders company,” its CEO said. 

    By • Oct. 27, 2025
  • A sign with Biogen's logo sits outside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Biogen licenses a possible immune drug from OrbiMed-backed biotech

    The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.

    By • Oct. 24, 2025
  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ventyx shares soar after study suggests cardiovascular benefits for experimental drug

    The drug’s effects on cardiovascular and inflammation markers outshined its failure to spur weight loss, analysts wrote.

    By Kristin Jensen • Oct. 23, 2025